Clinical Characteristics and Outcomes of Early-Onset Versus Late-Onset LGI1-Antibody Encephalitis

早发型与晚发型LGI1抗体脑炎的临床特征和预后

阅读:2

Abstract

BACKGROUND: Leucine-rich glioma-inactivated 1 antibody (LGI1-Ab) encephalitis predominantly affected older individuals, but has also been reported in younger patients. However, the demographic, clinical, and prognostic characteristics of early-onset LGI1-Ab encephalitis have yet to be systematically elucidated. This study aims to systematically describe the clinical features and outcomes of early-onset LGI1-Ab encephalitis and compare them with those of later-onset cases. METHODS: A total of 105 patients with LGI1-Ab encephalitis admitted to the Department of Neurology at Beijing Fengtai You'anmen Hospital were enrolled in this study between January 2019 and December 2024. All patients were divided into early-onset (age at onset younger than 50 years) and late-onset (age at onset 50 years or older) groups. Demographic, clinical, paraclinical, and prognostic data were compared between the two groups. RESULTS: Among the cohort, 30 (28.5%) patients had early-onset LGI1-Ab encephalitis, with a female predominance (17, 56.7%). Epileptic seizures, psychiatric and behavioral symptoms, and memory impairment were the most common symptoms both at disease onset and throughout the disease course. Compared to later-onset patients, early-onset patients exhibited a lower prevalence of faciobrachial dystonic seizures (FBDS) (p = 0.041) and hyponatremia (p = 0.003). Additionally, they had higher serum albumin (p = 0.012), lower CSF protein (p = 0.006), lower age-normalized QAlb (p = 0.001), and fewer epileptic waves (p = 0.041). As for prognosis, memory deficits (11/30, 36.7%) were the most common residual symptom at follow-up, and early-onset patients were less likely to relapse (p = 0.038). CONCLUSIONS: This study provides the first systematic characterization of early-onset LGI1-Ab encephalitis. Compared to late-onset cases, early-onset patients showed a lower incidence of hyponatremia, milder blood-brain barrier disruption, and fewer clinical relapses.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。